Inhalation Toxicology Testing Market Size to Hit USD 982.84 Million by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Inhalation Toxicology Testing Market

5.1. COVID-19 Landscape: Inhalation Toxicology Testing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Inhalation Toxicology Testing Market, By Study Type

8.1. Inhalation Toxicology Testing Market, by Study Type

8.1.1. Acute inhalation toxicity (single/limited exposure)

8.1.1.1. Market Revenue and Forecast

8.1.2. Carcinogenicity inhalation studies.

8.1.2.1. Market Revenue and Forecast

8.1.3. Repeated-dose inhalation toxicity (short-term, sub-chronic, chronic).

8.1.3.1. Market Revenue and Forecast

8.1.4. Developmental and reproductive (DART) inhalation studies.

8.1.4.1. Market Revenue and Forecast

8.1.5. Inhalation pharmacokinetics (PK/TK), ADME, and biodistribution (including radiolabeled).

8.1.5.1. Market Revenue and Forecast

8.1.6. Challenge/infectious-aerosol studies (BSL-2/3 as required).

8.1.6.1. Market Revenue and Forecast

8.1.7. In vitro inhalation assays (air-liquid interface [ALI], lung organoids) and NAMs.

8.1.7.1. Market Revenue and Forecast

8.1.8. Mechanistic/biomarker/-omics endpoints.

8.1.8.1. Market Revenue and Forecast

Chapter 9. Global Inhalation Toxicology Testing Market, By Exposure Mode/Atmosphere

9.1. Inhalation Toxicology Testing Market, by Exposure Mode/Atmosphere

9.1.1. Aerosol (particulate) — controlled MMAD/PSD

9.1.1.1. Market Revenue and Forecast

9.1.2. Vapour/gas exposures.

9.1.2.1. Market Revenue and Forecast

9.1.3. Whole-body exposure vs nose-only vs head-only vs intra-tracheal instillation.

9.1.3.1. Market Revenue and Forecast

9.1.4. Nebulised/device-specific dosing (pMDI, DPI, nebuliser).

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Inhalation Toxicology Testing Market, By Biological Model

10.1. Inhalation Toxicology Testing Market, by Biological Model

10.1.1. In vivo (rodent — mouse/rat; non-rodent — rabbit, dog; NHP)

10.1.1.1. Market Revenue and Forecast

10.1.2. In vitro (primary human airway cultures, ALI, co-culture airway models)

10.1.2.1. Market Revenue and Forecast

10.1.3. Ex vivo (precision-cut lung slices).

10.1.3.1. Market Revenue and Forecast

10.1.4. In silico/IVIVE and PBPK modelling.

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Inhalation Toxicology Testing Market, By Endpoint/Output

11.1. Inhalation Toxicology Testing Market, by Endpoint/Output

11.1.1. Histopathology and pulmonary pathology

11.1.1.1. Market Revenue and Forecast

11.1.2. Respiratory function (plethysmography, lung mechanics).

11.1.2.1. Market Revenue and Forecast

11.1.3. Clinical pathology (BAL, blood chemistries).

11.1.3.1. Market Revenue and Forecast

11.1.4. Biomarkers, cytokines, omics.

11.1.4.1. Market Revenue and Forecast

11.1.5. Deposited dose/dosimetry and aerosol characterization.

11.1.5.1. Market Revenue and Forecast

Chapter 12. Global Inhalation Toxicology Testing Market, By End-Market/Application

12.1. Inhalation Toxicology Testing Market, by End-Market/Application

12.1.1. Pharmaceutical

12.1.1.1. Market Revenue and Forecast

12.1.2. Medical devices

12.1.2.1. Market Revenue and Forecast

12.1.3. Tobacco and e-vapour/nicotine products.

12.1.3.1. Market Revenue and Forecast

12.1.4. Chemicals and agrochemicals

12.1.4.1. Market Revenue and Forecast

12.1.5. Others

12.1.5.1. Market Revenue and Forecast

Chapter 13. Global Inhalation Toxicology Testing Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Service/Study Type

13.1.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.1.3. Market Revenue and Forecast, by Biological Model

13.1.4. Market Revenue and Forecast, by Endpoint/Output

13.1.5. Market Revenue and Forecast, by End-Market/Application

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Service/Study Type

13.1.6.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.1.6.3. Market Revenue and Forecast, by Biological Model

13.1.6.4. Market Revenue and Forecast, by Endpoint/Output

13.1.6.5. Market Revenue and Forecast, by End-Market/Application

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Service/Study Type

13.1.7.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.1.7.3. Market Revenue and Forecast, by Biological Model

13.1.7.4. Market Revenue and Forecast, by Endpoint/Output

13.1.7.5. Market Revenue and Forecast, by End-Market/Application

13.2. Europe

13.2.1. Market Revenue and Forecast, by Service/Study Type

13.2.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.2.3. Market Revenue and Forecast, by Biological Model

13.2.4. Market Revenue and Forecast, by Endpoint/Output

13.2.5. Market Revenue and Forecast, by End-Market/Application

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Service/Study Type

13.2.6.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.2.6.3. Market Revenue and Forecast, by Biological Model

13.2.7. Market Revenue and Forecast, by Endpoint/Output

13.2.8. Market Revenue and Forecast, by End-Market/Application

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Service/Study Type

13.2.9.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.2.9.3. Market Revenue and Forecast, by Biological Model

13.2.10. Market Revenue and Forecast, by Endpoint/Output

13.2.11. Market Revenue and Forecast, by End-Market/Application

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Service/Study Type

13.2.12.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.2.12.3. Market Revenue and Forecast, by Biological Model

13.2.12.4. Market Revenue and Forecast, by Endpoint/Output

13.2.13. Market Revenue and Forecast, by End-Market/Application

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Service/Study Type

13.2.14.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.2.14.3. Market Revenue and Forecast, by Biological Model

13.2.14.4. Market Revenue and Forecast, by Endpoint/Output

13.2.15. Market Revenue and Forecast, by End-Market/Application

13.3. APAC

13.3.1. Market Revenue and Forecast, by Service/Study Type

13.3.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.3.3. Market Revenue and Forecast, by Biological Model

13.3.4. Market Revenue and Forecast, by Endpoint/Output

13.3.5. Market Revenue and Forecast, by End-Market/Application

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Service/Study Type

13.3.6.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.3.6.3. Market Revenue and Forecast, by Biological Model

13.3.6.4. Market Revenue and Forecast, by Endpoint/Output

13.3.7. Market Revenue and Forecast, by End-Market/Application

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Service/Study Type

13.3.8.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.3.8.3. Market Revenue and Forecast, by Biological Model

13.3.8.4. Market Revenue and Forecast, by Endpoint/Output

13.3.9. Market Revenue and Forecast, by End-Market/Application

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Service/Study Type

13.3.10.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.3.10.3. Market Revenue and Forecast, by Biological Model

13.3.10.4. Market Revenue and Forecast, by Endpoint/Output

13.3.10.5. Market Revenue and Forecast, by End-Market/Application

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Service/Study Type

13.3.11.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.3.11.3. Market Revenue and Forecast, by Biological Model

13.3.11.4. Market Revenue and Forecast, by Endpoint/Output

13.3.11.5. Market Revenue and Forecast, by End-Market/Application

13.4. MEA

13.4.1. Market Revenue and Forecast, by Service/Study Type

13.4.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.4.3. Market Revenue and Forecast, by Biological Model

13.4.4. Market Revenue and Forecast, by Endpoint/Output

13.4.5. Market Revenue and Forecast, by End-Market/Application

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Service/Study Type

13.4.6.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.4.6.3. Market Revenue and Forecast, by Biological Model

13.4.6.4. Market Revenue and Forecast, by Endpoint/Output

13.4.7. Market Revenue and Forecast, by End-Market/Application

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Service/Study Type

13.4.8.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.4.8.3. Market Revenue and Forecast, by Biological Model

13.4.8.4. Market Revenue and Forecast, by Endpoint/Output

13.4.9. Market Revenue and Forecast, by End-Market/Application

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Service/Study Type

13.4.10.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.4.10.3. Market Revenue and Forecast, by Biological Model

13.4.10.4. Market Revenue and Forecast, by Endpoint/Output

13.4.10.5. Market Revenue and Forecast, by End-Market/Application

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Service/Study Type

13.4.11.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.4.11.3. Market Revenue and Forecast, by Biological Model

13.4.11.4. Market Revenue and Forecast, by Endpoint/Output

13.4.11.5. Market Revenue and Forecast, by End-Market/Application

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Service/Study Type

13.5.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.5.3. Market Revenue and Forecast, by Biological Model

13.5.4. Market Revenue and Forecast, by Endpoint/Output

13.5.5. Market Revenue and Forecast, by End-Market/Application

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Service/Study Type

13.5.6.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.5.6.3. Market Revenue and Forecast, by Biological Model

13.5.6.4. Market Revenue and Forecast, by Endpoint/Output

13.5.7. Market Revenue and Forecast, by End-Market/Application

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Service/Study Type

13.5.8.2. Market Revenue and Forecast, by Exposure Mode/Atmosphere

13.5.8.3. Market Revenue and Forecast, by Biological Model

13.5.8.4. Market Revenue and Forecast, by Endpoint/Output

13.5.8.5. Market Revenue and Forecast, by End-Market/Application

Chapter 14. Company Profiles

14.1. Laboratory Corporation of America Holdings

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Charles River Laboratories, Inc.

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Eurofins Scientific

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Bureau Veritas

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Envigo

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Evotec AG

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Merck KGaA

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. SGS Group

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Pharmaceutical Product Development

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. LLC (PPD)

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The inhalation toxicology testing market size is expected to increase from USD 395.76 million in 2024 to USD 982.84 million by 2034.

The inhalation toxicology testing market is expected to grow at a compound annual growth rate (CAGR) of around 9.56% from 2025 to 2034.

The major players in the inhalation toxicology testing market include Laboratory Corporation of America Holdings, Charles River Laboratories, Inc., Eurofins Scientific, Bureau Veritas, Envigo, Evotec AG, Merck KGaA, SGS Group, Pharmaceutical Product Development, LLC (PPD), and WuXi AppTec.

The driving factors of the inhalation toxicology testing market are the increased demand for alternative testing methods and growing government funding for toxicology research

North America region will lead the global inhalation toxicology testing market during the forecast period 2025 to 2034.